Egypt Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	71
ISBN Number	1748-1864
Product Code	BMI01548

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

The Egyptian pharmaceutical market represents one of the least attractive in the Middle East and Africa (MEA) region. According to the latest BMI's Business Environment Ratings, Egypt remains in the twelfth position, above only Nigeria and Zimbabwe. Advantages offered by the country's vast population are, however, counterbalanced by difficult market access, excessive red tape and strict government price controls, among other factors. Notably, per capita consumption is only around US$15 per year, given the large segments of poor and rural population.

Nevertheless, the government seems to be moving in the right direction to attract foreign direct investment (FDI) and foreign companies. To this end, authorities have tabled proposals to remove the bioequivalency testing requirement even for drugs already on sale in advanced markets, although intellectual property (IP) enforcement continues to be questionable. According to figures released by the Organisation for Economic Co-operation and Development (OECD), Egypt supplies around 7% of all global pharmaceutical counterfeits. The figure for the local market can safely be considered much higher.

Nevertheless, by 2012, BMI forecasts that the market will top US$2.53mn, up from only around US$1.07bn in 2007. Price increases are expected to be one of the factors driving this growth. In January 2008, Egypt's Ministry of Health and Population (MoHP) agreed an 8% price increase, bowing to pressure from manufacturers worried by rising raw material costs. The price of the drugs had previously been unchanged for over a decade, despite significant rises in costs of production, clearly raising questions over their financial viability. While a welcome move for drugmakers, the poor may now find certain medicines becoming too expensive and out of their reach.

In other areas of healthcare, the modernisation of facilities is driving growth in the medical devices market. Egypt already represents one of the key markets for medical devices in the Middle East area, albeit a very competitive one. Most of the devices are supplied by foreign companies, which often act through a local agent. The medical devices market in Egypt, presently estimated to be worth around US$225mn, is forecast to grow at an annual rate of around 10% over the coming few years and thus provide considerable commercial opportunities for companies in the field.

Content

Executive Summary
- Egypt Pharmaceuticals And Healthcare Industry SWOT
- Egypt Political SWOT..............Error! Bookmark not defined.
- Egypt Economic SWOT............Error! Bookmark not defined.
- Egypt Business Environment SWOT ........................................................................................................................Error! Bookmark not defined.
- Pharmaceutical Business Environment Ratings
- Limits To Potential Returns
- Risks To Realisation Of Returns
- Egypt - Market Summary
- Regulatory Regime
- Intellectual Property Developments
- IP Shortcomings
- Counterfeit Medicines
- Free Trade Agreements
- Pricing Regime
- Reimbursement Regime
- Recent Pricing And Reimbursement Developments
- Industry Developments
- Health Profile
- Healthcare Sector
- Healthcare Insurance
- Pharmaceutical Sector
- Domestic Sector
- Foreign Manufacturing Sector
- Retail Pharmacies
- Herbal And OTC Medicine
- Research And Development Activity
- Medical Devices
- Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Patented Market Forecast
- Generics Drug Market Forecast
- OTC Market Forecast
- Export/Import Market Forecast
- Other Healthcare Data
- Key Risks To BMI Forecasts
- Competitive Landscape
- Company Monitors
- Multinational Profiles
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Pfizer
- Novartis
- Bristol-Myers Squibb (BMS)
- Merck & Co
- AstraZeneca
- Domestic Companies
- Egyptian International Pharmaceutical Industries Co (EIPICO)
- SEDICO
- Alexandria Pharmaceuticals
- Amoun Pharmaceutical (APC)
- Holding Company for Biological Products & Vaccines (Vacsera)
- Misr Pharmaceuticals
- BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Weighting
- Sources
List of Tables
- Table: Pharmaceutical Business Environment Ratings
- Table: Losses Due To Counterfeit Drugs In MEA, Moving Annual Total Ending September 2006
- Table: Egypt - Drug Expenditure And Prescription Market Indicators (US$mn unless otherwise stated)
- Table: Egypt's Health Expenditure Forecasts
- Table: Economic Activity
- Table: Egypt's Patented Drug Market Forecast (US$mn unless otherwise stated)
- Table: Egypt's Generics And Patented Drug Market Forecasts
- Table: Egypt's OTC Market Forecasts (US$mn unless otherwise stated)
- Table: Egypt's Pharmaceutical Trade Forecasts (US$mn unless otherwise stated)
- Table: Egypt - Other Health Indicators
- Table: Pharmaceutical Holding Companies
- Table: Egypt - Top 10 Pharmaceutical Companies By Market Share 2005
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

About this Product

Delivery Details

PDF:Immediate delivery

Ask a question about this product?

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted